Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 37

1.

Risks and benefits with bevacizumab: evidence and clinical implications.

Kurkjian C, Kim ES.

Ther Adv Drug Saf. 2012 Apr;3(2):59-69. doi: 10.1177/2042098611430109. Review.

PMID:
25083226
[PubMed]
Free PMC Article
2.

Cardiac safety results from a phase II, open-label, multicenter, pilot study of two docetaxel-based regimens plus bevacizumab for the adjuvant treatment of subjects with node-positive or high-risk node-negative breast cancer.

Hurvitz SA, Bosserman LD, Chan D, Hagenstad CT, Kass FC, Smith FP, Rodriguez GI, Childs BH, Slamon DJ.

Springerplus. 2014 May 12;3:244. doi: 10.1186/2193-1801-3-244. eCollection 2014.

PMID:
24860718
[PubMed]
Free PMC Article
3.
4.

Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy.

Vacchelli E, Aranda F, Eggermont A, Galon J, Sautès-Fridman C, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2014 Jan 1;3(1):e27048. Review.

PMID:
24605265
[PubMed]
Free PMC Article
5.

An updated meta-analysis of fatal adverse events caused by bevacizumab therapy in cancer patients.

Huang H, Zheng Y, Zhu J, Zhang J, Chen H, Chen X.

PLoS One. 2014 Mar 5;9(3):e89960. doi: 10.1371/journal.pone.0089960. eCollection 2014.

PMID:
24599121
[PubMed - in process]
Free PMC Article
6.

Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions.

Vasudev NS, Reynolds AR.

Angiogenesis. 2014 Jul;17(3):471-94. doi: 10.1007/s10456-014-9420-y. Epub 2014 Jan 31.

PMID:
24482243
[PubMed - in process]
Free PMC Article
7.

Antiangiogenesis therapy for breast cancer: an update and perspectives from clinical trials.

Fakhrejahani E, Toi M.

Jpn J Clin Oncol. 2014 Mar;44(3):197-207. doi: 10.1093/jjco/hyt201. Epub 2014 Jan 27. Review.

PMID:
24474817
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Heterogeneity of tumor vasculature and antiangiogenic intervention: insights from MR angiography and DCE-MRI.

Zhu W, Kato Y, Artemov D.

PLoS One. 2014 Jan 23;9(1):e86583. doi: 10.1371/journal.pone.0086583. eCollection 2014.

PMID:
24466160
[PubMed - in process]
Free PMC Article
9.

Which patients with metastatic breast cancer benefit from subsequent lines of treatment? An update for clinicians.

Palumbo R, Sottotetti F, Riccardi A, Teragni C, Pozzi E, Quaquarini E, Tagliaferri B, Bernardo A.

Ther Adv Med Oncol. 2013 Nov;5(6):334-50. doi: 10.1177/1758834013508197.

PMID:
24179488
[PubMed]
Free PMC Article
10.

A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2-Negative breast CancEr (the RESILIENCE study): study protocol for a randomized controlled trial.

Baselga J, Costa F, Gomez H, Hudis CA, Rapoport B, Roche H, Schwartzberg LS, Petrenciuc O, Shan M, Gradishar WJ.

Trials. 2013 Jul 22;14:228. doi: 10.1186/1745-6215-14-228.

PMID:
23876062
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Drug resistance and the role of combination chemotherapy in improving patient outcomes.

Yardley DA.

Int J Breast Cancer. 2013;2013:137414. doi: 10.1155/2013/137414. Epub 2013 Jun 24.

PMID:
23864953
[PubMed]
Free PMC Article
12.

Water exchange-minimizing DCE-MRI protocol to detect changes in tumor vascular parameters: effect of bevacizumab/paclitaxel combination therapy.

Zhu W, Kato Y, Artemov D.

MAGMA. 2014 Apr;27(2):161-70. doi: 10.1007/s10334-013-0389-0. Epub 2013 Jun 27.

PMID:
23807596
[PubMed - in process]
Free PMC Article
13.

Comment on 'The efficacy and toxicity of gemcitabine, carboplatin and bevacizumab in metastatic breast cancer'.

Kitchen D, O'Brien M, Hughes B, Gill I, Rumbles S, Ellis P, Stebbing J.

Br J Cancer. 2013 Jul 23;109(2):526-8. doi: 10.1038/bjc.2013.279. Epub 2013 Jun 11. No abstract available.

PMID:
23756861
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

The addition of bevacizumab to standard chemotherapy in breast cancer: which patient benefits the most?

Kruse V, Denys H, Van Den Broecke R, Van Belle S, Cocquyt V.

Springerplus. 2013 May 1;2(1):202. Print 2013 Dec.

PMID:
23710429
[PubMed]
Free PMC Article
15.

Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers.

Jain RK.

J Clin Oncol. 2013 Jun 10;31(17):2205-18. doi: 10.1200/JCO.2012.46.3653. Epub 2013 May 13. Review.

PMID:
23669226
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Biomarkers for anti-angiogenic therapy in cancer.

Wehland M, Bauer J, Magnusson NE, Infanger M, Grimm D.

Int J Mol Sci. 2013 Apr 29;14(5):9338-64. doi: 10.3390/ijms14059338.

PMID:
23629668
[PubMed]
Free PMC Article
17.

Trial watch: Monoclonal antibodies in cancer therapy.

Vacchelli E, Eggermont A, Galon J, Sautès-Fridman C, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2013 Jan 1;2(1):e22789.

PMID:
23482847
[PubMed]
Free PMC Article
18.

Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer.

Miles DW, de Haas SL, Dirix LY, Romieu G, Chan A, Pivot X, Tomczak P, Provencher L, Cortés J, Delmar PR, Scherer SJ.

Br J Cancer. 2013 Mar 19;108(5):1052-60. doi: 10.1038/bjc.2013.69. Epub 2013 Feb 19.

PMID:
23422754
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

The impact of Bevacizumab (Avastin) on survival in metastatic solid tumors--a meta-analysis and systematic review.

Amit L, Ben-Aharon I, Vidal L, Leibovici L, Stemmer S.

PLoS One. 2013;8(1):e51780. doi: 10.1371/journal.pone.0051780. Epub 2013 Jan 22. Review.

PMID:
23349675
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Antiangiogenic therapy for cancer: an update.

Al-Husein B, Abdalla M, Trepte M, Deremer DL, Somanath PR.

Pharmacotherapy. 2012 Dec;32(12):1095-111. doi: 10.1002/phar.1147. Review.

PMID:
23208836
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk